Mr. Aemad Aslam MBA
President, MindPharma
Member of the Healthcare Council
Council Member Biography
Aemad Aslam, BPharm, MBA, RPh, is the President of MindPharma, a pharmacy and retail strategy consulting group. Most recently, he has consulted with a PBM, Prime Therapeutics, in Texas, a subsidiary of Blue Cross Blue Shield. He also has served as an Executive Team Leader for Pharmacy at the Target Corporation, Minnesota. Mr. Aslam has over 14 years of experience in the pharmacy retail and PBM sectors. Previously, he served as a Co-Founder of Temp360 Healthcare Solutions, a provider of software technology to healthcare staffing agencies, and as a Founder of PharmFirst, a pharmacy staffing agency. He has also served as a District Pharmacy Supervisor at the Eckerd Corporation and a Pharmacy Manager at CVS. Mr. Aslam regularly consults retail drug stores, pharmaceutical companies, and PBMs on strategies and analytics. He evaluates pricing models, valuation, and market analysis. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- President, MindPharma
- 2004 - 2007
- Executive Team Leader for Pharmacy, TARGET CORPORATION
- 2004 - 2004
- Pharmacy Manager, CVS CAREMARK CORPORATION
- 2002 - 2004
- Founder, Business Strategist, Temp 360 Healthcare Solutions
- 1996 - 2002
- District Pharmacy Supervisor, ECKERD CORPORATION
- 1995 - 1996
- Pharmacy Intern, St Lukes Hospital
GLG NewsSM Analyses by Aemad Aslam(?)
-
Thriving in a time of adversity - Sun Pharma pounces on shortage by getting approval on Oxycodone
April 13, 2009
Sun Pharma gets USFDA's nod to market painkillers | www.hindu.com
Sun Pharma can greatly benefit from the nationwide shortage of Oxycodone Immediate Release Tablet, by getting approval from the FDA on their own generic. With recent recalls from different manufacturers, and the shortage of a comparable product Morphine Sulphate, the FDA currently estimates that return to normal supply levels of Oxycodone may occur in approximately 2 months, during which time Sun Pharma can capitalize on the shortage by securing longer term contracts with wholesalers.
-
Aurobindo Pharma's Escitalopram will be a big mover ... when it comes out in 2011
March 5, 2009
Aurobindo Pharma receives tentative approval for Escitalopram | www.indiainfoline.com
Forest's Lexapro commands a $2.5+ billion USD market share, just in the US. Due to such a high volume of the brand product, Aurobindo's tentative approval on Lexapro's generic Escitalopram will be a great opportunity - primarily if they can procure a 6 month period of exclusivity from the FDA. Additionally, despite being a brand name product, Lexapro holds an 8%+ year over year increase in the past 3 years. Hence, the market for the drug in September of 2011 when the patent runs out will be closer to a $3 billion market.
-
Teva's Generic Imitrex commands market of Sumatriptan
February 26, 2009
Teva Announces Approval and Launch of Generic Imitrex(R) Tablets | www.pipelinereview.com
With the 180 day exclusivity, Teva is already commanding the market of the generic Imitrex - Sumatriptan oral tablets. Teva maintains an AB rating of the generic that will render most insurance companies to push brand name Imitrex by GlaxoSmithKline to a non-formulary tier, skyrocketing the generic's sales. Already, different wholesalers are reporting a backorder on Teva's generics. Additionally, Teva's pricing point is very favorable to itself, despite Dr Reddy's prior entrance.
-
Acquisitions of Indian Pharma on the extended horizon by Brand name pharma
February 23, 2009
Pharma cos on lookout for Indian drug firms | economictimes.indiatimes.com
Acquisitions of various Indian generic pharmaceuticals is likely on the horizon for brand name manufacturers. However, this is not an immediate concern. I would see more consolidations in the US and other Western markets first.
-
Sun Pharma - much stronger with acquisitions including Taro
February 17, 2009
As valuations dip, Sun Pharma is in M&A mode | economictimes.indiatimes.com
Sun Pharma is attempting to gain market share in the world largest market - the US market. Sun Pharma is clearly expanding it product base with venturing into topical (dermatological) and pediatric segments, and with vertical integration as with raw materials suppliers. Sequentially, I would see SunPharma to be a leader in the US market within this decade, unless other Indian manufacturers encroach in this market.
GLG Study Groups with Aemad Aslam(?)
| Study Group Name | No. Members |
|---|---|
| Pharmacists (US) | 2086 |
| Generic Drug Economic Experts | 777 |
| Economic Experts on Managed Care | 741 |
| Medical Tourism Experts | 353 |
| Formulary Design Experts | 253 |
GLG Live Meetings with Aemad Aslam(?)
Aemad Aslam has not participated in any GLG Live Meetings.